ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1650

The Route Of T Cell Priming Determines The Requirement For IL-23 In The Development Of Arthritis

Alison Finnegan1, Yanxia Cao1 and Susan Olalekan2, 1Dept of Medicine, Rush University Medical Center, Chicago, IL, 2Immunology, Rush University Medical Center, Chicago, IL

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: IL-23, T cells and cytokines

  • Tweet
  • Email
  • Print
Session Information

Title: T-cell Biology in Autoimmune Diseases

Session Type: Abstract Submissions (ACR)

Background/Purpose: Rheumatoid arthritis is a very heterogeneous disease and distinct molecular mechanisms may underlie the disease process.  IL-23 is an important cytokine for the expansion of Th17 cells and in the development of a number of autoimmune diseases. IL-23 is a heterodimeric cytokine composed of p19 and p40 subunits.  IL-12, an important cytokine for differentiation of Th1 cells, is composed of p40 and p35. We have reported in proteoglycan-induced arthritis (PGIA) that the route of antigen exposure, intraperitoneal (i.p.) versus subcutaneous (s.c.), determines the Th1/Th17 phenotype respectively of the T cells involved in arthritis.  In this study, we assess the contribution of IL-23 to the development of PGIA induced by i.p. or s.c. immunization.

Methods: Wild type (WT), p19-/- and p40-/- female BALB/c mice (>3 months of age) were immunized i.p. or s.c. with 50 ug recombinant G1 domain of human PG in adjuvant dimethydioctadecy ammonium bromide (DDA) 3 times at 3-week intervals. Paws were examined every third day for arthritis assessed based on the intensity of erythema and swelling on a score of 1-4. ELISA measured cytokines from CD4+T cells and spleen cells re-stimulated in vitro with PG. T cell intracellarular cytokines were assessed by flow cytometry.

Results: In p19-/- mice, arthritis severity was significantly reduced in s.c. immunized mice, but only mildly reduced in i.p. immunized mice.  In p40-/- mice, arthritis was significantly reduced in both i.p. and s.c. immunized mice.  Levels of IL-17 were suppressed in splenocytes and inguinal lymph nodes (LN) from p19-/- mice either s.c. or i.p. immunization.  However, IFN-γ levels were reduced only in p19-/- mice after s.c. immunization.  To determine if suppression of IFN-γ was an early event after T cell priming we assess splenocyte responses early after immunization on day 9, IFN-γ was not suppressed in p19-/- mice. In p40-/-mice, IFN-γ and IL-17 responses were reduced after id or i.p. immunization.  

Conclusion: The present results demonstrate that IL-23 plays a critical role in the development of arthritis after s.c. immunization and a minor role after i.p. immunization. Since p40 is a shared subunit of IL-12 and IL-23 reduction in arthritis after i.p. or s.c. follows the requirement of IL-12 in Th1 responses after i.p. immunization and the requirement for IL-23 in Th17 responses after s.c. immunization.  These data suggest that activation of T cells in different compartments or routes of antigen exposure could affect the dominance of a Th1 versus a Th17 response.


Disclosure:

A. Finnegan,
None;

Y. Cao,
None;

S. Olalekan,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-route-of-t-cell-priming-determines-the-requirement-for-il-23-in-the-development-of-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology